{"symbol":"BMY","fiscalQuarter":"Q2-2026","reportDate":"2026-07-30","reportTime":"BMO","status":"upcoming","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q2-2026","preBrief":{"companySnapshot":"Bristol-Myers Squibb Company (BMY) is a major player in the pharmaceuticals sector, focusing on developing innovative medicines for serious diseases. With a market cap of $119 billion, the company is significant in the health care industry, particularly in oncology, immunology, and cardiovascular treatments.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of the company's profitability and will help investors gauge financial health this quarter.","consensus":"Not available"},{"name":"Revenue Growth","why":"Revenue growth will indicate how well the company is performing in the market and whether its products are gaining traction.","consensus":"Not available"},{"name":"Pipeline Updates","why":"Updates on drug development and clinical trials are crucial for assessing future growth potential.","consensus":"Not available"}],"lastQuarterRecap":{"summary":"In Q1-2026, Bristol-Myers Squibb reported an EPS of $1.58, surpassing estimates by 9.65%. The stock reacted positively, gaining 5.21% the following day.","promises":[]},"wallStreetExpectations":{"summary":"Overall expectations for Bristol-Myers Squibb are mixed, with a strong history of beating EPS estimates but uncertainty about future revenue growth.","bullCase":"If the company continues its trend of positive EPS surprises, it could lead to further stock appreciation and increased investor confidence.","bearCase":"Conversely, if the company fails to meet expectations or provides weak guidance on revenue, it could lead to a significant decline in stock price."},"optionsSignal":{"impliedMove":"13.88%","context":"The options market is pricing in a significant potential move, suggesting that investors are anticipating volatility around the earnings report."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+9.65%","reaction":"+5.21%"},{"quarter":"Q4-2025","epsSurprise":"+9.28%","reaction":"+3.30%"},{"quarter":"Q3-2025","epsSurprise":"+10.14%","reaction":"+7.09%"},{"quarter":"Q2-2025","epsSurprise":"-12.63%","reaction":"-5.81%"},{"quarter":"Q1-2025","epsSurprise":"+19.52%","reaction":"+0.33%"}],"pivotalQuestions":[{"question":"What will be the EPS for Q2-2026?","whyItMatters":"Given the company's strong EPS beat rate, this number will be critical in determining market sentiment post-earnings."},{"question":"What updates will be provided on the drug pipeline?","whyItMatters":"Investors are keen to know about the progress of key drugs in development, as this could impact future revenue and growth prospects."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $1.70 or higher would confirm the bull case, indicating strong profitability.","bearTrigger":"An EPS below $1.40 would confirm the bear case, suggesting potential issues in performance.","context":"The core debate this quarter revolves around the company's ability to maintain its strong earnings trajectory amid competitive pressures."},"scenarioPlaybook":{"beatAndRaise":"If Bristol-Myers Squibb beats expectations, history suggests a stock increase of around 4.21%, confirming positive market sentiment.","inLineCautious":"If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.","miss":"A miss could lead to a decline of approximately 5.81%, reflecting disappointment in the company's performance."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"X of Y (Z%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.4%, with a raw directional average of +0.6% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating the potential for Bristol-Myers Squibb to exceed EPS expectations based on its historical performance.","supportingPoints":["The company has an 88% EPS beat rate, indicating strong potential for positive surprises.","Options pricing suggests a larger move than historical averages, indicating heightened investor expectations.","Recent positive trends in the pharmaceutical sector may not be fully reflected in current estimates."],"riskToConsensus":"If the EPS comes in below $1.40, the market's confidence in the company's growth narrative could significantly weaken."},"whatToListenFor":["Any updates on key drug trials and their potential market impact.","Management's outlook on revenue growth for the upcoming quarters.","Details on cost management strategies and their effect on profitability.","Insights into competitive pressures within the pharmaceutical industry.","Any changes in guidance or expectations for future earnings."],"metaDescription":"Bristol-Myers Squibb (BMY) reports Q2 2026 earnings July 30. Investors are keenly watching for EPS and pipeline updates."}}